{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T00:43:03Z","timestamp":1786236183316,"version":"build-2736575974"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012659","name":"Foundation for Innovative Research Groups of the National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017596","name":"Natural Science Basic Research Program of Shaanxi Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017596","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ejphar.2026.179132","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T23:18:27Z","timestamp":1783725507000},"page":"179132","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Aspirin enhances the anti-tumour activity of lapatinib in HER2-positive breast cancer"],"prefix":"10.1016","volume":"1030","author":[{"given":"Hanbin","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panpan","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaili","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junxi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junqing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingmei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2026.179132_bib3","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.ctrv.2009.12.012","article-title":"Lapatinib and HER2 status: results of a meta-analysis of randomized phase III trials in metastatic breast cancer","volume":"36","author":"Amir","year":"2010","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.ejphar.2026.179132_bib4","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1053\/j.seminoncol.2004.03.042","article-title":"The role of COX-2 inhibition in breast cancer treatment and prevention","volume":"31","author":"Arun","year":"2004","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.ejphar.2026.179132_bib5","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/oncolo\/oyad186","article-title":"Aspirin use and survival among patients with breast cancer: a systematic review and meta-analysis","volume":"29","author":"Baker","year":"2024","journal-title":"Oncologist"},{"key":"10.1016\/j.ejphar.2026.179132_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12051097","article-title":"Deactivation of glutaminolysis sensitizes PIK3CA-Mutated colorectal cancer cells to aspirin-induced growth inhibition","volume":"12","author":"Boku","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.ejphar.2026.179132_bib10","doi-asserted-by":"crossref","first-page":"6784","DOI":"10.1158\/1078-0432.CCR-12-1785","article-title":"Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer","volume":"18","author":"Chandarlapaty","year":"2012","journal-title":"Clin. Cancer Res. : an official journal of the American Association for Cancer Research"},{"key":"10.1016\/j.ejphar.2026.179132_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2022.102426","article-title":"Aspirin promotes RSL3-induced ferroptosis by suppressing mTOR\/SREBP-1\/SCD1-mediated lipogenesis in PIK3CA-mutant colorectal cancer","volume":"55","author":"Chen","year":"2022","journal-title":"Redox Biol."},{"key":"10.1016\/j.ejphar.2026.179132_bib12","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s11912-017-0605-6","article-title":"Role of aspirin in breast cancer survival","volume":"19","author":"Chen","year":"2017","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.ejphar.2026.179132_bib13","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nature10983","article-title":"The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups","volume":"486","author":"Curtis","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2026.179132_bib14","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.ctrv.2015.08.001","article-title":"Mechanisms of lapatinib resistance in HER2-driven breast cancer","volume":"41","author":"D'Amato","year":"2015","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.ejphar.2026.179132_bib15","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/annonc\/mdf125","article-title":"Cyclooxygenase-2 (COX-2), aromatase and breast cancer: a possible role for COX-2 inhibitors in breast cancer chemoprevention","volume":"13","author":"Davies","year":"2002","journal-title":"Ann. Oncol. : official journal of the European Society for Medical Oncology"},{"key":"10.1016\/j.ejphar.2026.179132_bib16","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1053\/j.gastro.2012.02.050","article-title":"Aspirin inhibits mTOR signalling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells","volume":"142","author":"Din","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejphar.2026.179132_bib18","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/nrc.2016.4","article-title":"Aspirin and colorectal cancer: the promise of precision chemoprevention","volume":"16","author":"Drew","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejphar.2026.179132_bib20","doi-asserted-by":"crossref","first-page":"9221","DOI":"10.1158\/0008-5472.CAN-08-1740","article-title":"Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR\/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235","volume":"68","author":"Eichhorn","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejphar.2026.179132_bib22","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/bjc.2014.264","article-title":"Aspirin use and survival after the diagnosis of breast cancer: a population-based cohort study","volume":"111","author":"Fraser","year":"2014","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejphar.2026.179132_bib23","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-78646-y","article-title":"Combination treatment with a PI3K\/Akt\/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells","volume":"10","author":"Fujimoto","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2026.179132_bib24","doi-asserted-by":"crossref","first-page":"16349","DOI":"10.18632\/oncotarget.7648","article-title":"AMPK-mediated up-regulation of mTORC2 and MCL-1 compromises the anti-cancer effects of aspirin","volume":"7","author":"Gao","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejphar.2026.179132_bib25","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1056\/NEJMoa064320","article-title":"Lapatinib plus capecitabine for HER2-positive advanced breast cancer","volume":"355","author":"Geyer","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2026.179132_bib26","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1200\/JCO.2007.14.0590","article-title":"Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer","volume":"26","author":"Gomez","year":"2008","journal-title":"J. Clin. Oncol. : official journal of the American Society of Clinical Oncology"},{"key":"10.1016\/j.ejphar.2026.179132_bib27","doi-asserted-by":"crossref","first-page":"188","DOI":"10.2174\/1568009611313020008","article-title":"Novel approaches for molecular targeted therapy of breast cancer: interfering with PI3K\/AKT\/mTOR signalling","volume":"13","author":"Grunt","year":"2013","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.ejphar.2026.179132_bib28","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1634\/theoncologist.2015-0138","article-title":"Prospective biomarker analysis of the randomized CHER-LOB study evaluating the dual Anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-Positive breast cancer","volume":"20","author":"Guarneri","year":"2015","journal-title":"Oncologist"},{"key":"10.1016\/j.ejphar.2026.179132_bib30","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1001\/jamaoncol.2020.7338","article-title":"Aspirin use and risk of colorectal cancer among older adults","volume":"7","author":"Guo","year":"2021","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ejphar.2026.179132_bib32","doi-asserted-by":"crossref","first-page":"14372","DOI":"10.1073\/pnas.1303204110","article-title":"Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies","volume":"110","author":"Hanker","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejphar.2026.179132_bib34","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/nrd1902","article-title":"Exploiting the PI3K\/AKT pathway for cancer drug discovery","volume":"4","author":"Hennessy","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejphar.2026.179132_bib35","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1158\/0008-5472.CAN-16-2400","article-title":"Aspirin suppresses growth in PI3K-Mutant breast cancer by activating AMPK and inhibiting mTORC1 signaling","volume":"77","author":"Henry","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejphar.2026.179132_bib36","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1200\/JCO.2009.22.7918","article-title":"Aspirin intake and survival after breast cancer","volume":"28","author":"Holmes","year":"2010","journal-title":"J. Clin. Oncol. : official journal of the American Society of Clinical Oncology"},{"key":"10.1016\/j.ejphar.2026.179132_bib38","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1124\/mol.112.082743","article-title":"Lapatinib-mediated cyclooxygenase-2 expression via epidermal growth factor receptor\/HuR interaction enhances the aggressiveness of triple-negative breast cancer cells","volume":"83","author":"Hsia","year":"2013","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.179132_bib39","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s10549-012-2252-9","article-title":"PI3K independent activation of mTORC1 as a target in lapatinib-resistant ERBB2+ breast cancer cells","volume":"136","author":"Jegg","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.ejphar.2026.179132_bib40","doi-asserted-by":"crossref","first-page":"891","DOI":"10.3389\/fphar.2020.00891","article-title":"A comprehensive review of clinical cardiotoxicity incidence of FDA-approved small-molecule kinase inhibitors","volume":"11","author":"Jin","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.179132_bib41","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/annonc\/mdp304","article-title":"Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines","volume":"21","author":"Kataoka","year":"2010","journal-title":"Ann. Oncol. : official journal of the European Society for Medical Oncology"},{"key":"10.1016\/j.ejphar.2026.179132_bib42","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S1470-2045(09)70087-7","article-title":"Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study","volume":"10","author":"Kaufman","year":"2009","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejphar.2026.179132_bib44","doi-asserted-by":"crossref","first-page":"531","DOI":"10.4143\/crt.2022.221","article-title":"PIK3CA mutation is associated with poor response to HER2-Targeted therapy in breast cancer patients","volume":"55","author":"Kim","year":"2023","journal-title":"Cancer research and treatment"},{"key":"10.1016\/j.ejphar.2026.179132_bib45","first-page":"1045","article-title":"The trastuzumab era: current and upcoming targeted HER2+ breast cancer therapies","volume":"10","author":"Kreutzfeldt","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.ejphar.2026.179132_bib48","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1158\/1078-0432.CCR-08-1080","article-title":"Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer","volume":"15","author":"Lin","year":"2009","journal-title":"Clin. Cancer Res. : an official journal of the American Association for Cancer Research"},{"key":"10.1016\/j.ejphar.2026.179132_bib50","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1200\/JCO.2014.55.7876","article-title":"PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer","volume":"32","author":"Loibl","year":"2014","journal-title":"J. Clin. Oncol. : official journal of the American Society of Clinical Oncology"},{"key":"10.1016\/j.ejphar.2026.179132_bib49","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1016\/S0140-6736(16)32417-5","article-title":"HER2-positive breast cancer","volume":"389","author":"Loibl","year":"2017","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.ejphar.2026.179132_bib52","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1200\/JCO.2014.55.2158","article-title":"PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer","volume":"33","author":"Majewski","year":"2015","journal-title":"J. Clin. Oncol. : official journal of the American Society of Clinical Oncology"},{"key":"10.1016\/j.ejphar.2026.179132_bib55","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2165\/00003495-200262010-00008","article-title":"Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2","volume":"62","author":"McKeage","year":"2002","journal-title":"Drugs"},{"key":"10.1016\/j.ejphar.2026.179132_bib56","article-title":"PI3K\/AKT\/mTOR signalling pathway in breast cancer: from molecular landscape to clinical aspects","volume":"22","author":"Miricescu","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2026.179132_bib57","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1001\/jamaoncol.2015.2286","article-title":"The evolving landscape of HER2 targeting in breast cancer","volume":"1","author":"Moasser","year":"2015","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ejphar.2026.179132_bib58","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1038\/onc.2014.153","article-title":"PRKACA mediates resistance to HER2-targeted therapy in breast cancer cells and restores anti-apoptotic signalling","volume":"34","author":"Moody","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.ejphar.2026.179132_bib59","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15041102","article-title":"Potential role of non-steroidal anti-inflammatory drugs in colorectal cancer chemoprevention for inflammatory bowel disease: an umbrella review","volume":"15","author":"Newman","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.ejphar.2026.179132_bib60","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1634\/theoncologist.2011-0461","article-title":"Lapatinib for advanced or metastatic breast cancer","volume":"17","author":"Opdam","year":"2012","journal-title":"Oncologist"},{"key":"10.1016\/j.ejphar.2026.179132_bib62","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1556\/MOnkol.53.2009.4.6","article-title":"[lapatinib treatment-option in trastuzumab-resistant breast cancer]","volume":"53","author":"Pik\u00f3","year":"2009","journal-title":"Magy. Onkol."},{"key":"10.1016\/j.ejphar.2026.179132_bib63","volume":"6","author":"Rasti","year":"2022"},{"key":"10.1016\/j.ejphar.2026.179132_bib64","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.drudis.2015.12.003","article-title":"COX-2 inhibitors: a novel strategy in the management of breast cancer","volume":"21","author":"Regulski","year":"2016","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejphar.2026.179132_bib65","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s10549-017-4533-9","article-title":"Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer","volume":"167","author":"Rimawi","year":"2018","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.ejphar.2026.179132_bib69","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1634\/theoncologist.2008-0816","article-title":"FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER2","volume":"13","author":"Ryan","year":"2008","journal-title":"Oncologist"},{"key":"10.1016\/j.ejphar.2026.179132_bib70","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.ejphar.2026.179132_bib71","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1126\/science.2470152","article-title":"Studies of the HER2\/neu proto-oncogene in human breast and ovarian cancer","volume":"244","author":"Slamon","year":"1989","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.ejphar.2026.179132_bib72","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ejphar.2026.179132_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217112","article-title":"PI3K PROTAC overcomes the lapatinib resistance in PIK3CA-mutant HER2 positive breast cancer","volume":"598","author":"Zhang","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejphar.2026.179132_bib78","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1002\/jcb.24611","article-title":"Autophagy stimulates apoptosis in HER2-overexpressing breast cancers treated by lapatinib","volume":"114","author":"Zhu","year":"2013","journal-title":"J. Cell. Biochem."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001429992600614X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001429992600614X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T00:27:30Z","timestamp":1786235250000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001429992600614X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":52,"alternative-id":["S001429992600614X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2026.179132","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aspirin enhances the anti-tumour activity of lapatinib in HER2-positive breast cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2026.179132","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"179132"}}